Comparative Pharmacology
Head-to-head clinical analysis: AGGRASTAT versus PLETAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRASTAT versus PLETAL.
AGGRASTAT vs PLETAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirofiban is a reversible antagonist of glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by blocking fibrinogen binding.
Cilostazol inhibits phosphodiesterase III (PDE3), increasing cAMP levels in platelets and vascular smooth muscle, leading to platelet inhibition and vasodilation.
A loading dose of 25 mcg/kg administered intravenously over 3 minutes, followed by a maintenance infusion of 0.15 mcg/kg/min for up to 18 hours. For patients with severe renal impairment (GFR <30 mL/min), the maintenance infusion rate is reduced to 0.075 mcg/kg/min.
100 mg orally twice daily, administered at least 30 minutes before or 2 hours after meals.
None Documented
None Documented
Terminal half-life: ~2 hours; clinical context: requires continuous IV infusion for sustained antiplatelet effect
Terminal half-life of cilostazol is approximately 11-13 hours; for active metabolites 3,4-dehydro-cilostazol (about 4-6 times more active) half-life is similar. Steady state achieved within a few days.
Renal: 65% unchanged drug; biliary/fecal: minimal (<5%)
Renal (approximately 77% as metabolites, <1% unchanged); fecal (approximately 18%)
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent